PUBLIC COMPANY
save$TSHATaysha Gene Therapies, Inc.
$TSHA4.6300-2.32%Dallas, TX, USupdated 15h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
- phase3A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
- phase2Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 10, 26SELLNagendran Sukumar· President and Head of R&D−$892K↗
routine RSU / option mechanics (2)
- Apr 10, 26option exerciseNagendran Sukumar · President and Head of R&D19,021 sh
- Apr 10, 26option exerciseNagendran Sukumar · President and Head of R&D19,021 sh
🐶 Hiring Signal
News
- Mikhail, Davis on board with regulatory framework tailored to rare disease therapiesNewly permanent CBER and CDER directors Karim Mikhail and Michael Davis are widely expected to continue the FDA’s efforts toward an adaptive framework for rare disease therapies. If approved by the…biospace · 12d ago
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that